Picture of CERo Therapeutics Holdings logo

CERO CERo Therapeutics Holdings Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Annual cashflow statement for CERo Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2022
December 31st
2023
December 31st
2024
December 31st
Period Length:12 M12 M12 M
Source:PROSPECTUSPROSPECTUS10-K
Standards:
USG
USG
USG
Status:FinalFinalFinal
Net Income/Starting Line-11.8-7.29-8.3
Depreciation
Non-Cash Items0.9410.499-6.89
Unusual Items
Other Non-Cash Items
Changes in Working Capital-1.30.541.84
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-11.7-5.79-12.9
Capital Expenditures-0.6940
Purchase of Fixed Assets
Cash from Investing Activities-0.6940
Financing Cash Flow Items0-0.039-0.02
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities0.0060.57213.7
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-12.4-5.220.812